Pharma Leaders
Refine search
Latest Pharma Leaders News & Features
Pharmaceutical
A Q&A with the man who heads the UK business of the privately-held Italian drugmaker. 3 May 2024
Biotechnology
This week in The Pharma Letter Podcast, we are speaking with the chief executive of British drug development company Ellipses Pharma. 23 January 2024
Biotechnology
On Tuesday, US biotech company Novavax, which is advancing protein-based vaccines with its Matrix-M adjuvant, announced a timely update with its Nuvaxovid XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted). 1 November 2023
Biotechnology
In the world of outsourced clinical research, ICON is a big fish in a pond full of other increasingly big fish. In this episode of the podcast, we chat with the company’s CCO, George McMillan. 24 October 2023
Biotechnology
The past year has been one of ups and downs for Blueprint Medicines Corporation, a US precision medicines company developing therapies for people with cancer and blood disorders. 20 September 2023
Biotechnology
US biotech Cytokinetics is seeking to develop medicines that treat cardiovascular and neuromuscular diseases of impaired muscle function. 15 August 2023
Biotechnology
The need for medications that bring relief for patients affected by migraine is enormous. 26 July 2023
Biotechnology
Gilead Sciences subsidiary Kite prides itself on being a leader in the development of cell therapies, a claim backed by its pioneering work with Yescarta (axicabtagene ciloleucel). 5 June 2023
Pharmaceutical
As the crowds descend on Chicago for the annual meeting of the American Society of Clinical Oncology (ASCO), The Pharma Letter interviews Eisai chief medical officer Kirk Shepard about his firm’s progress in oncology. 1 June 2023
Biotechnology
Earlier this month, UK biotech Bicycle Therapeutics entered a strategic collaboration with Germany’s Bayer. 26 May 2023
Biotechnology
The progress quietly made by Sino-American biotech company BeiGene with its oral Bruton tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib) since 2019 has been nothing short of remarkable. 30 March 2023
Biotechnology
After an illustrious career as chief scientific officer at Johnson & Johnson, Dr Paul Stoffels is ready for a new chapter in his home country, with Belgian biotech Galapagos. 2 February 2023
Pharmaceutical
In Boston, Massachusetts, one company is now making significant headway in the development of an innovative treatment for serious disorders of the liver. In this week’s episode of The Pharma Letter Podcast, we are joined by Albireo CEO Ron Cooper, for a discussion of his company’s clinical goals and strategic focus. 31 October 2022
Biotechnology
For years, commentators have observed that drug prices in the USA are significantly higher than elsewhere in the world. As the US Congress debates government action, we speak with EQRx chief executive Melanie Nallicheri about her company's market-based solution to high costs. 22 July 2022
Pharmaceutical
One UK-based company is looking to transform the way metabolic disorders are treated, leveraging many of the same AI-based techniques used to great effect elsewhere. MultiOmic Health chief executive Robert Thong discusses his firm's progress. 4 July 2022
Biotechnology
Prothena has an intriguing Alzheimer’s vaccine, dubbed PRX123, which is yet to enter the clinic but which scientists believe could stop the development of both Abeta and tau in the brain. 6 June 2022
Biotechnology
The race to meet sudden, stratospheric demand for new anti-obesity meds is hotting up, but Novo Nordisk CEO Lars Fruergaard Jørgensen takes a collegiate approach. 26 May 2022
Pharmaceutical
In the USA and in Europe, interest in the potential for artificial intelligence to transform different aspects of the life sciences industry is at an all-time high. 12 May 2022
Biotechnology
In recent years there has been an explosion of digital tools in the life sciences, but as with everything in pharma and biotech, their value hinges on the strength of the underlying data, making it essential to capture research in a robust way. One company, Labstep, aims to help scientists achieve this. 5 April 2022
Biotechnology
A feature on the recent fortunes of and prospects for Belgian drugmaker UCB. 25 March 2022
Pharmaceutical
A Q&A with the man who heads the UK business of the privately-held Italian drugmaker. 3 May 2024
Biotechnology
This week in The Pharma Letter Podcast, we are speaking with the chief executive of British drug development company Ellipses Pharma. 23 January 2024
Biotechnology
On Tuesday, US biotech company Novavax, which is advancing protein-based vaccines with its Matrix-M adjuvant, announced a timely update with its Nuvaxovid XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted). 1 November 2023
Biotechnology
In the world of outsourced clinical research, ICON is a big fish in a pond full of other increasingly big fish. In this episode of the podcast, we chat with the company’s CCO, George McMillan. 24 October 2023
Biotechnology
The past year has been one of ups and downs for Blueprint Medicines Corporation, a US precision medicines company developing therapies for people with cancer and blood disorders. 20 September 2023
Biotechnology
US biotech Cytokinetics is seeking to develop medicines that treat cardiovascular and neuromuscular diseases of impaired muscle function. 15 August 2023
Biotechnology
The need for medications that bring relief for patients affected by migraine is enormous. 26 July 2023
Biotechnology
Gilead Sciences subsidiary Kite prides itself on being a leader in the development of cell therapies, a claim backed by its pioneering work with Yescarta (axicabtagene ciloleucel). 5 June 2023
Pharmaceutical
As the crowds descend on Chicago for the annual meeting of the American Society of Clinical Oncology (ASCO), The Pharma Letter interviews Eisai chief medical officer Kirk Shepard about his firm’s progress in oncology. 1 June 2023
Biotechnology
Earlier this month, UK biotech Bicycle Therapeutics entered a strategic collaboration with Germany’s Bayer. 26 May 2023
Biotechnology
The progress quietly made by Sino-American biotech company BeiGene with its oral Bruton tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib) since 2019 has been nothing short of remarkable. 30 March 2023
Biotechnology
After an illustrious career as chief scientific officer at Johnson & Johnson, Dr Paul Stoffels is ready for a new chapter in his home country, with Belgian biotech Galapagos. 2 February 2023
Pharmaceutical
In Boston, Massachusetts, one company is now making significant headway in the development of an innovative treatment for serious disorders of the liver. In this week’s episode of The Pharma Letter Podcast, we are joined by Albireo CEO Ron Cooper, for a discussion of his company’s clinical goals and strategic focus. 31 October 2022
Biotechnology
For years, commentators have observed that drug prices in the USA are significantly higher than elsewhere in the world. As the US Congress debates government action, we speak with EQRx chief executive Melanie Nallicheri about her company's market-based solution to high costs. 22 July 2022
Pharmaceutical
One UK-based company is looking to transform the way metabolic disorders are treated, leveraging many of the same AI-based techniques used to great effect elsewhere. MultiOmic Health chief executive Robert Thong discusses his firm's progress. 4 July 2022
Biotechnology
Prothena has an intriguing Alzheimer’s vaccine, dubbed PRX123, which is yet to enter the clinic but which scientists believe could stop the development of both Abeta and tau in the brain. 6 June 2022
Biotechnology
The race to meet sudden, stratospheric demand for new anti-obesity meds is hotting up, but Novo Nordisk CEO Lars Fruergaard Jørgensen takes a collegiate approach. 26 May 2022
Pharmaceutical
In the USA and in Europe, interest in the potential for artificial intelligence to transform different aspects of the life sciences industry is at an all-time high. 12 May 2022
Biotechnology
In recent years there has been an explosion of digital tools in the life sciences, but as with everything in pharma and biotech, their value hinges on the strength of the underlying data, making it essential to capture research in a robust way. One company, Labstep, aims to help scientists achieve this. 5 April 2022
Biotechnology
A feature on the recent fortunes of and prospects for Belgian drugmaker UCB. 25 March 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze